Loading stock data…
Aldeyra Therapeutics (ALDX)
$2.00+0.18 (+9.56%)
Market OpenUpdated 3:09 PM EDT
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Aldeyra Therapeutics, Inc. in the Healthcare sector is trading at $1.99 with a market capitalization of $111M. Wall Street consensus targets $7.60 (5 analysts), implying a +281.9% move over the next 12 months. The stock is currently near its 52-week low of $1.07, remaining 48.4% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +281.9% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$3.55M↑ | -$6.67M↑ | -$8.00M↑ | -$10.17M↑ | -$10.43M |
| Net Income | -$3.45M↑ | -$6.46M↑ | -$7.69M↑ | -$9.77M↑ | -$9.93M |
Peer Comparison
JNJUNHPFE
Fundamentals
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical t...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$110.99M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-64.92%
Volume
Today's trading volume
1.19M
Recent News
CEO, President & Director of Aldeyra Therapeutics Picks Up 18% More Stock
Investors who take an interest in Aldeyra Therapeutics, Inc. ( NASDAQ:ALDX ) should definitely note that the CEO...
Aldeyra Therapeutics Eyes FDA Feedback as Dry Eye Drug Faces Make-or-Break Moment
Aldeyra Therapeutics (NASDAQ:ALDX) Chief Executive Todd Brady said the company expects near-term feedback from the U.S. Food and Drug Administration on its dry eye disease candidate reproxalap, following a third complete response letter tied to efficacy questions. Speaking at a Jefferies fireside c
3 Promising Penny Stocks With Market Caps Reaching $300M
The market remained flat over the last week, but it is up 26% over the past year, with earnings forecast to grow by 17% annually. Investing in penny stocks—once a buzzword but now more of a niche—can still open doors to growth opportunities, typically in smaller or newer companies. We've identified three penny stocks that combine balance sheet strength with potential for outsized gains, giving investors the chance to discover hidden value in quality companies.
Upstart Holdings Leads These 3 Stocks Estimated To Be Trading Below Fair Value
Over the last 7 days, the United States market has risen by 1.1%, and over the past 12 months, it is up by an impressive 27%, with earnings expected to grow by 17% per annum in the coming years. In this context of robust market performance, identifying stocks that are trading below their fair value can be a strategic move for investors seeking opportunities for potential growth and value.
3 Stocks That May Be Undervalued According To Analysts In May 2026
Over the last 7 days, the United States market has risen by 1.1%, contributing to a remarkable 27% climb over the past year, with earnings forecasted to grow by 17% annually. In this thriving environment, identifying stocks that may be undervalued can present opportunities for investors seeking potential value plays amidst strong market performance.